Viridian Therapeutics Inc — 四半期キャッシュフロー (NASDAQ:VRDN) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 742.4 M660.98 M582.32 M577.14 M899.42 M 負債合計 70.76 M56.51 M67.16 M74.17 M177.25 M 純資産合計 671.64 M604.47 M515.17 M502.97 M722.17 M 負債および純資産合計 742.4 M660.98 M582.32 M577.14 M899.42 M 有利子負債合計 20.58 M20.68 M20.79 M20.89 M84.18 M 純負債 -697.02 M-615.91 M-542.61 M-470.01 M-790.52 M

ニュース

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN)

Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-04-02

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian TherapeuticsがLeerinkカンファレンスで市場拡大を展望

Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion

Viridian TherapeuticsがTD Cowen会議でTED治療における戦略的展開を発表

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment

StifelがViridian Therapeuticの株式レーティングを生物製剤承認申請審査で再確認